Crossmark

Low-dose dobutamine in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (the DOBERMANN-D trial): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial

Crossref DOI link: https://doi.org/10.1186/s13063-024-08567-y

Published Online: 2024-10-30

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Holle, Sarah Louise Duus

Kunkel, Joakim Bo

Hassager, Christian

Pecini, Redi

Wiberg, Sebastian

Palm, Pernille

Holmvang, Lene

Bang, Lia Evi

Kjærgaard, Jesper

Thomsen, Jakob Hartvig

Engstrøm, Thomas

Møller, Jacob Eifer

Lønborg, Jacob Thomsen

Søholm, Helle

Frydland, Martin
Funding

Funding for this research was provided by:

Copenhagen University
License Information

Text and Data Mining valid from 2024-10-30

Version of Record valid from 2024-10-30
More Information

Article History

Received: 9 July 2024

Accepted: 18 October 2024

First Online: 30 October 2024

Declarations

:

: The protocol and its subsequent amendments have been reviewed and approved by the sponsor, the Regional Ethical Committee (H-21045751) and the Danish Medicines Agency (2021073315) with respect to scientific content and compliance with applicable research and human subjects’ regulations.Informed consent forms, patient information, recruitment materials, and other requested documents have likewise been reviewed and approved by the Regional Ethical Committee. Written, informed consent to participate is obtained from all patients.

: Not applicable—no identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. The participant information materials and informed consent form are available from the corresponding author on request.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below